Romyelocel-L - Cellerant Therapeutics

Drug Profile

Romyelocel-L - Cellerant Therapeutics

Alternative Names: CLT-008; hMPC - Cellerant Therapeutics; Human myeloid progenitor cells - Cellerant Therapeutics

Latest Information Update: 03 Jul 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Cellerant Therapeutics
  • Class Cell therapies; Stem cell therapies
  • Mechanism of Action Cell replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase II Neutropenia

Most Recent Events

  • 04 Jun 2018 Safety and efficacy data from phase II trial in Acute myeloid leukemia released by Cellerant Therapeutics
  • 01 Jun 2018 Interim adverse events and efficacy data from the phase II trial for Neutropenia presented at the 54th Annual Meeting of the American Society of Clinical Oncology (ASCO-2018)
  • 22 Sep 2017 Cellerant Therapeutics completes a phase II trial for Neutropenia (Chemotherapy-induced) in USA (IV) (NCT02282215)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top